PARG and ovarian carcinoma: However, PARG depletion did not show synthetic lethality with BRCA1 mutations in different cancer cell lines (Noll et al. 2016), the PARG inhibitor JA2131 efficiently killed BRCA-proficient cancer cells (Houl et al. 2019), and only one out of six tested ovarian cancer cells with BRCA1/2 mutations showed sensitivity to PARG inhibition with PDD00017273 (Pillay et al. 2019).